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Two new series 2-(2-(1-(1-methyl-1H-benzo[d]imidazol-2-yl)ethylidene)hydrazinyl)-4-(aryl)thiazoles 3a-k and 2-(2-(1-
(1-methyl-1H-benzo[d]imidazol-2-yl)ethyl)hydrazinyl)-4-(aryl)thiazoles 4a-k encompassing benzimidazole incorporated 
with thiazole have been synthesized using rational approach. These thiazole derivatives 3a-k have been reduced at the site of 
formation of Schiff base (>CH=N−) to obtain final compounds 4a-k. Compounds 3a-k and 4a-k have been screened for 
their in vitro antibacterial and antifungal actions against four strains each. Among the screened compounds, 3d, 3e, 3f, 3g, 
3j, 3k, 4d, 4e, 4f and 4k have emerged as highly effective antibacterial agents, while compounds 3d, 3e, 3f, 3k and 4k have 
come out as most potent antifungal molecules. Comparison of outcomes of antibacterial and antifungal screening of 
compounds 3a-k and 4a-k directed that antimicrobial potential of unreduced derivatives 3a-k is higher than reduced 
derivatives 4a-k. SAR study reveals that presence of halogen (-F, -Cl, -Br) substituents is accountable for significant 
antimicrobial potential. Also the results of preliminary MTT cytotoxicity assay on HeLa cells indicates that antimicrobial 
activity of 3e, 3f, 3g, 3j, 3k, 4e, 4f and 4k is accompanied by low extent of cytotoxic concentrations. 
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As resistance to antimicrobial drugs is widespread; 
there is an increase necessity for the recognition of 
novel structures which could lead to the design of 
new, potent and less toxic antimicrobial agents. The 
chemistry and pharmacology of benzimidazoles have 
been of great interest to medicinal chemistry1 because 
its derivatives possessed countless biological 
activities such as antioxidant2,3, antimicrobial4, 
anthelmintic2, anticancer5,6, antihypertensive7, anti-
HIV8, anti-inflammatory9, analgesic10,11, 
antiprotozoal12 and anti-hepatitis B virus activity13. A 
variety of benzimidazoles are in use, like 
thiabendazole and flubendazole (anthelmintic), 
omeprazole and lansoprazole (antiulcerative) and 
astemizole (antihistaminic). 
On the other hand thiazole system has found broad 
application in drug development for the treatment of 
inflammation14, hypertension15, bacterial infection16, 
HIV infections17 and cancer18,19. The thiazolium ring 
present in vitamin B1 serves as an electron sink, and 
its coenzyme form is important for the 
decarboxylation of α-keto acids20. It has been reported 
that 2,4-disubstituted thiazoles possess very good 
antitumor21, antioxidative22, antiviral22 and 
antifungal23 activities. 
The benzimidazoles and thiazoles still remain one 
of the most versatile classes of compounds against 
microbes and therefore, are useful substructures for 
further molecular exploration. Keeping the above 
facts in view, we deliberated it of interest to 
synthesize 2-substituted benzimidazole incorporated 
with thiazoles for their antimicrobial activity. We 
have synthesized a series of thiazoles bearing N-
methyl benzimidazole by replacing the quinoline 
motif in our previously synthesized compounds24 5a-g 
and 6a-g and screened them for their antibacterial 
property. In this attempt, we got excellent 
antibacterial results. Structural relevance of title 
compounds 3a-k and 4a-k with previously 
synthesized compounds is shown in Figure 1. 
Induced by above indicated observations, we have 
planned to synthesize molecules having 
benzimidazole and thiazole entities possessing 
noteworthy pharmacological properties. In 
continuation of our research for new, discerning, 
nontoxic, safe and efficient antimicrobial agents, we 
studied the antimicrobial potential of the title 
molecules against vast range of different human 
pathogenic micro-organisms to evaluate concrete 
SAR results. Additionally cytotoxicity studies were 




also carried out on HeLa cell lines to evaluate the 
capability of these compounds to obstruct the cell 
proliferation. 
 
Result and Discussion 
The multiple reaction sequences employed to 
synthesize title compounds are shown in Scheme I. 
Compound 1 which is starting material was  
prepared by following already reported  
experimental procedure25,26. Treatment of 1-(1-
methyl-1H-benzo[d]imidazol-2-yl)ethenone 1 with 
thiosemicarbazide in presence of methanol as a 
solvent under stirring at 50°C gave intermediate 2-(1-
(1-methyl-1H-benzo[d]imidazol-2-yl)ethylidene) 
hydrazinecarbothioamide2 in good yield and high 
purity. 
Presence of N-substituted thiourea or 
thiosemicarbazone as a terminal fragment in 2 makes 
it a versatile precursor for the Hantzsch thiazole 
synthesis with aromatic α-haloketones in alcoholic 
medium under stirring for 1 h to obtain 2-(2-(1-(1-
methyl-1H-benzo[d]imidazol-2-yl)ethylidene)hydrazinyl)- 
4-(aryl)thiazoles 3a-k in high yield without any 
further purification. 
Finally the title molecules 2-(2-(1-(1-methyl-1H-
benzo[d]imidazol-2-yl)ethyl)hydrazinyl)-4-
(aryl)thiazoles 4a-k was conveniently obtained by 
reduction of compounds 3a-k using sodium 
borohydride as a selective reducing agent under 
stirring for half an hour at 0-5°C to subside 
exothermic addition of sodium borohydride.Synthetic 
route and reaction conditions employed for the 
synthesis of compounds 3a-k and 4a-k has been given 
in Scheme I. The structures of all the newly 
synthesized compounds were established by elemental 
analysis, FTIR, 1H and 13C NMR and mass spectral 
studies. 
The investigation of antibacterial and antifungal 
screening data revealed that all the tested compounds 
3a-k and 4a-k showed very good to moderate 
inhibition at 6.25–12.5µg/mL in DMSO. The 
compounds 3d, 3e, 3f, 3g, 3k, 4e, 4f and 4k showed 
 
Figure 1 — Structural relevance of title compounds 3a-k and 4a-k




Scheme I — Synthetic route for compounds 3a-k and 4a-k 




comparatively very good activity against all the 
bacterial strains with respect to standard drug 
ciprofloxacin. This high activity profile is attributed 
to the presence of halogen functions (-F, -Cl, -Br) to 
the phenyl ring at position 4 of thiazole ring. The 
compounds 3c,3i, 4g, 4h, 4i and 4j exhibited 
moderate antibacterial activity compared to that of 
standard against all the bacterial strains. Compound 
3jshowed very good activity against Escherichia coli. 
The compound 4d showed very good activity against 
Pseudomonas aeruginosa and Pseudomonas aureus. 
The compounds 3d, 3e, 3f, 3g, 3k and 4k showed 
comparatively very good activity against all the 
fungal strains. The compounds 3b, 3c, 3i, 3j, 4d, 4e, 
4f, and 4j exhibited moderate activity against all 
fungal strains. Results showed that combination of 
benzimidazole with thiazole ring gave an enhanced 
biological effect against all the bacterial strains. 
Overall decrease in antibacterial and antifungal 
activity with respect to compounds 3a-k has been 
observed in compounds 4a-k which were obtained by 
reduction of the CH=N- fragment of compounds 3a-k. 
Comparison of MIC for antibacterial activity with 
respect to standard drug ciprofloxacin and antifungal 
activity with respect to standard drug 
ciclopiroxolamine of compounds 3a-k and 4a-k is 
shown in Figure 2 and Figure 3 respectively. 
 
Result of Cytotoxicity Studies 
The synthesized novel molecules 3a-k and 4a-k 
were evaluated for in vitro cytotoxicity against human 
cervical cancer cell line (HeLa) by the 3-[4,5-
dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide 
(MTT) colorimetric assay31, which measures the 
reduction of tetrazolium bromide salt into a formazan 
dye by mitochondrial dehydrogenases in treated 
versus untreated cells. Outcome of this assay 
unquestionably indicate that compounds 3e, 3f,  
3g, 3j, 3k, 4e, 4f and 4k do not acquire 
cytotoxicityatconcentration of 100 µM (IC50 >100 
µM). All other molecules own moderate toxicity 
against HeLa cell lines. It was ensured that none of 
the tested molecules acquire noteworthy cytotoxicity 
effect on HeLa cell lines, indicating that compounds 
 
 




Figure 3 — Comparison of MIC (μg/mL) for antifungal activity of the compounds 3a-k and 4a-k with respect to standard drug 
Ciclopiroxolamine 




were promising candidates for in vivo use as 
antimicrobial agents. 
 
Structure activity relation study 
From the results of antimicrobial potential, it can 
be concluded that reduced derivatives possess lover 
antimicrobial activity than unreduced derivatives.  
A study of structure–activity relationship revealed 
that the presence of a halogen (-F, -Cl, -Br) function 
at 2nd and 4th position of the phenyl ring as seen with 
compounds 3d, 3e,3f, 3j, 3k, 4e, 4f and 4k was found 
to be the main structural requirement for retaining 
antimicrobial profile. Antimicrobial potential of these 
compounds is also supported by lower level of 
cytotoxicity. Further compound 3d is found to be very 
good active against microbial strain but possess 
moderate cytotoxicity. Based on this observation it 
can be summerise that presence of halogen substituent 
at ortho position is responsible for moderate 
cytotoxicity and the same on either para or ortho and 
para are accounted for lower level of cytotoxicity. 
 
Material and Method 
All the chemicals were purchased from Sigma 
Aldrich, Merck and S. D. Fine chemicals-India. 
Commercial grade solvents were used and were 
distilled before use. Solvents used were extra dried. 
Elemental analysis (% C, H, N) data were obtained by 
using Perkin Elmer 2400-CHN analyzer, IR spectra 
were recorded on IR Thermo nicolet 200 using KBr 
pellets technique. 1H NMR and spectra were recorded 
on BrukerAvance(400 MHz) and 13C NMR were 
recorded on Varian Mercury-400, 100 MHzNMR 
Spectrometer by using TMS as an internal standard 
and CDCl3 as solvent. Mass spectra were recorded on 
Schimadzu LC-MS 2010 spectrophotometer. Melting 
points were recorded on Gallenkamp apparatus and 
were uncorrected. TLC experiments were performed 
on alumina backed silica gel 60 F245 plates  
(E. Merck). Iodine and Ultraviolet (UV) lamp was 
used for visualisation of the spots on TLC.Chemical 
shifts are reported in ppm (δ). The signals are 
designated as follows: s, singlet; d, doublet; t, triplet; 





Already reported compound 1 as a starting material 
was synthesized according to literature method25,26. 
 
Preparation of 2-(1-(1-methyl-1H-benzo[d] 
imidazol-2-yl)ethylidene)hydrazinecarbothioamide (2) 
To a solution of compound 1 (0.01 mole) in 
methanol was added thiosemicarbazide (0.01 mole) 
and the mixture was refluxed for 1 hr. The mixture 
was allowed to attain RT and poured onto crushed ice 
with stirring. The separated solid was filtered and 
washed with water. The solid was recrystallized from 
methanol. 
Yield 80%; mp 168-170°C. IR (KBr) υmax/cm
–1: 
3355, 3460 (N-H, NH2), 3129 (C-H, aromatic), 2930, 
2855 (C-H, -CH3), 1620 (C=N), 1250 (C=S); 
1H NMR (400 MHz, CDCl3, δ, ppm): 2.61 (s, 3H), 
3.94 (s, 3H), 6.64 (s, 2H), 7.26 (d, J = 8.0 Hz, 2H), 
7.60 (d, J = 7.6 Hz, 2H), 8.57 (s, 1H, ); 13C NMR (100 
MHz, CDCl3, δ, ppm): 180, 150, 138.5, 136.8, 131.3, 
121.2, 120.3, 112.4, 108.6, 32.1, 18.2; LC-MS (m/z): 
247 (M+). Anal. calcd for C11H13N5S: C-53.42, H-
5.30, N-28.32; found: C-53.39, H-5.32, N-28.22. 
 
General procedure for the synthesis of 2-(2-(1-(1-
methyl-1H-benzo[d]imidazol-2-
yl)ethylidene)hydrazinyl)-4-(aryl)thiazoles (3a-k) 
To a solution of compound 2 (0.01 mole) and 
corresponding 2-bromo-arylethanone (0.01 mole) in 
methanol was stirred for 1 hr. The separated solid was 
filtered, air dried and recrystallized from chloroform 
as pale yellow solid. Reaction completion was 
monitored by TLC using 7:3 (n-hexane:ethyl acetate) 
as mobile phase. Characterization data of compounds 




Yield 77%; mp 130-132°C. IR (KBr) υmax/cm
–1: 
3373 (N-H, broad), 3150 (C-H, aromatic), 2955, 2886 
(C-H, -CH3), 1623 (C=N); 
1H NMR (400 MHz, 
CDCl3, δ, ppm): 2.63 (s, 3H, C-CH3), 3.97 (s, 3H,  
N-CH3), 6.72 (s, 1H, Ar-H of thiazole), 7.24 -7.61  
(m, 9H, Ar-H), 8.93 (s, 1H, -NH);13C NMR  
(100 MHz, CDCl3, δ, ppm): 15.6, 36.3, 107.0, 114.0, 
119.4, 123.0, 125.3, 132.5, 133.4, 135.2, 138.4, 140.9, 
145.5, 154.3, 159.4, 176.9; LC-MS (m/z): 347 (M+). 
Anal. calcd. For C19H17N5S: C-65.60, H-4.85,  




Yield 71%; mp 132-134°C. IR (KBr) υmax/cm
–1: 
3375 (N-H stretching, broad), 3151 (C-H, aromatic), 
2953, 2884 (C-H, -CH3), 1624 (C=N); 
1H NMR (400 




MHz, CDCl3, δ, ppm): 2.34 (s, 3H), 2.79 (s, 3H), 3.79 
(s, 3H), 6.79 (s, 1H), 7.28 -7.67 (m, 8H), 8.50 (s, 1H); 
13C NMR (100 MHz, CDCl3, δ, ppm): 15.4, 21.5, 
36.5, 107.2, 114.4, 119.2, 123.3, 125.5, 132.3, 134.0, 
135.4, 138.2, 140.4, 145.7, 154.1, 159.4, 176.9; LC-
MS (m/z): 361 (M+). Anal. calcd. For C20H19N5S: C-






Yield 72%; mp 137-139°C. IR (KBr) υmax/cm
–1: 
3374 (N-H, broad), 3152 (C-H, aromatic), 2959, 2885 
(C-H, -CH3), 1626 (C=N); 
1H NMR (400 MHz, 
CDCl3, δ, ppm): 2.70 (s, 3H), 2.83 (s, 3H), 3.67  
(s, 3H), 6.70 (s, 1H), 7.30-7.65 (m, 8H), 8.52 (s, 1H); 
13C NMR (100 MHz, CDCl3, δ, ppm): 15.5, 36.3, 
55.8, 107.0, 114.4, 116.2, 119.6, 123.4, 125.1, 126.3, 
138.6, 140.4, 145.2, 154.2, 159.2, 176.2; LC-MS 
(m/z): 377 (M+). Anal. calcd. For C20H19N5OS:  






Yield 70%; mp 148-150°C. IR (KBr) υmax/cm
–1: 
3376 (N-H, broad), 3159 (C-H, aromatic), 2960, 2889 
(C-H, -CH3), 1629 (C=N), 736 (C-Cl); 
1H NMR (400 
MHz, CDCl3, δ, ppm): 2.61 (s, 3H), 3.65 (s, 3H), 6.65 
(s, 1H), 7.21-7.64 (m, 8H), 8.55 (s, 1H); 13C NMR 
(100 MHz, CDCl3, δ, ppm): 15.6, 36.4, 107.1, 114.3, 
119.3, 123.2, 128.7, 129.5, 132.3, 132.9, 134.2, 134.5, 
136.6, 140.4, 145.6, 150.8, 159.5, 176.5, LC-MS 
(m/z): 381 (M+), 383 (M+2). Anal. calcd. For 
C19H16ClN5S: C-59.71, H-4.20, N-18.35; Found: C-





Yield 70%; mp 151-153°C. IR (KBr) υmax/cm
–1: 
3379 (N-H, broad), 3157 (C-H, aromatic), 2953, 2887 
(C-H, -CH3), 1624 (C=N), 737 (C-Cl); 
1H NMR (400 
MHz, CDCl3, δ, ppm): 2.80 (s, 3H), 3.66 (s, 3H), 6.67 
(s, 1H), 7.23-7.62 (m, 8H), 8.59 (s, 1H); 13C NMR 
(100 MHz, CDCl3, δ, ppm): 15.6, 36.1, 107.0, 114.4, 
119.6, 123.4, 126.3, 131.1, 133.4, 134.2, 134.3,  
140.9, 145.5, 154.3, 159.4, 176.9; LC-MS (m/z): 381 
(M+), 383 (M+2). Anal. calcd. For C19H16ClN5S:  






Yield 69%; mp 150-152°C. IR (KBr) υmax/cm
–1: 
3372 (N-H, broad), 3156 (C-H, aromatic), 2952, 2885 
(C-H, -CH3), 1624 (C=N), 600 (C-Br); 
1H NMR  
(400 MHz, CDCl3, δ, ppm): 2.60 (s, 3H), 3.67 (s, 3H), 
6.73 (s, 1H), 7.29-7.70 (m, 8H), 8.84 (s, 1H);  
13C NMR (100 MHz, CDCl3, δ, ppm): 15.4, 36.2, 
107.1, 114.3, 119.2, 123.0, 125.4, 130.6, 132.2, 132.3, 
134.2, 140.0, 145.5, 154.2, 159.3, 176.6; LC-MS 
(m/z): 427 (M+), 429 (M+2). Anal. calcd. For 
C19H16BrN5S: C-53.60, H-3.80, N-16.40; Found:  




Yield 65%; mp 149-151°C. IR (KBr) υmax/cm
–1: 
3380 (N-H, broad), 3155 (C-H, aromatic), 2957, 2882 
(C-H, -CH3), 1633 (C=N), 1020 (C-F); 
1H NMR (400 
MHz, CDCl3, δ, ppm): 2.75 (s, 3H), 3.68 (s, 3H), 6.80 
(s, 1H), 7.26-7.64 (m, 8H), 8.81 (s, 1H); 13C NMR 
(100 MHz, CDCl3, δ, ppm): 15.2, 36.4, 107.0, 114.3, 
117.2, 119.4, 123.1, 130.4, 132.8, 134.8, 140.2, 145.6, 
154.2, 159.2, 164.7, 1768; LC-MS (m/z): 365 (M+), 
367 (M+2). Anal. calcd. For C19H16FN5S: C-62.50, H-





Yield 66%; mp 162-164°C. IR (KBr) υmax/cm
–1: 
3369 (N-H, broad), 3154 (C-H, aromatic), 2960, 2891 
(C-H, -CH3), 1620 (C=N), 1344, 1451 (-NO2); 
1H NMR (400 MHz, CDCl3, δ, ppm): 2.66 (s, 3H), 
3.67 (s, 3H), 6.82 (s, 1H), 7.32-7.72 (m, 8H), 8.82 (s, 
NH, 1H); 13C NMR (100 MHz, CDCl3, δ, ppm): 15.6, 
36.4, 107.2, 114.4, 119.6, 123.2, 126.6, 128.4, 138.0, 
141.1, 145.3, 147.7, 154.2, 159.4, 176.5; LC-MS 
(m/z): 392 (M+). Anal. calcd. For C19H16N6O2S: C-





Yield 71%; mp 136-138°C. IR (KBr) υmax/cm
–1: 
3368 (N-H, broad), 3160 (C-H, aromatic), 2950, 2881 
(C-H, -CH3), 2241 (CN, sharp), 1636 (C=N); 




1H NMR (400 MHz, CDCl3, δ, ppm): 2.63 (s, 3H), 
3.66 (s, 3H), 6.66 (s, 1H), 7.27-7.64 (m, 8H), 8.70 (s, 
1H); 13C NMR (100 MHz, CDCl3, δ, ppm): 15.8, 36.5, 
107.4, 114.6, 116.2, 119.8, 123.4, 126.3, 132.9, 138.6, 
137.5, 140.7, 145.2, 154.4, 159.6, 176.2; LC-MS 
(m/z): 372 (M+). Anal. calcd. For C20H16N6S: C-64.45, 





Yield 78%; mp 140-142°C. IR (KBr) υmax/cm
–1: 
3381 (N-H, broad), 3158 (C-H, aromatic), 2956, 2892 
(C-H, -CH3), 1637 (C=N), 743 (C-Cl); 
1H NMR (400 
MHz, CDCl3, δ, ppm): 2.45 (s, C-3H), 3.67 (s, 3H), 
6.69 (s, 1H), 7.33-7.71 (m, 7H), 8.72 (s, 1H); 
13C NMR (100 MHz, CDCl3, δ, ppm): 15.4, 36.3, 
107.1, 114.3, 119.4, 123.2, 129.4, 130.2, 133.3, 133.9, 
134.9, 136.4, 138.2, 140.0, 145.5, 151.0, 159.6, 176.0; 
LC-MS (m/z): 415 (M+), 417 (M+2), 419 (M+4). Anal. 
calcd. For C19H15Cl2N5S: C-54.78, H-3.60, N-16.78; 
Found: C-54.81, H-3.63, N-16.82%. 
 
4-(2,4-difluorophenyl)-2-(2-((1-methyl-1H-benzo 
[d]imidazol-2-yl)ethylidene) hydrazinyl)thiazole (3k) 
Yield 70%; mp 138-140°C. IR (KBr) υmax/cm
–1: 
3378 (N-H, broad), 3165 (C-H, aromatic), 2953, 2883 
(C-H, -CH3), 1635 (C=N), 1025 (C-F); 
1H NMR  
(400 MHz, CDCl3, δ, ppm): 2.50 (s, 3H), 3.69 (s, 3H), 
6.71 (s, 1H), 7.27-7.80 (m, 7H), 8.88 (s, 1H);  
13C NMR (100 MHz, CDCl3, δ, ppm): 15.8, 36.7, 
104.1, 107.2, 114.2, 115.2, 119.5, 121.3, 123.3, 132.7, 
136.4, 140.5, 141.7, 147.6, 154.3, 159.4, 161.1, 176.9; 
LC-MS (m/z): 383 (M+), 385 (M+2). Anal. calcd. For 
C19H15F2N5S: C-59.48, H-3.90, N-18.30; Found:  
C-59.52, H-3.94, N-18.27%. 
 
General procedure for the synthesis of 2-(2-(1-(1-
methyl-1H-benzo[d]imidazol-2-yl) 
ethyl)hydrazinyl)-4-(aryl)thiazole (4a-k) 
In a conical flask, compound 3a-k (0.01 mole) was 
taken in methanol (50 mL) and cooled to 0-5°C in an 
ice bath on a magnetic stirrer. To this mixture, sodium 
borohydride (0.01 mole) was added portion wise 
within half an hour at 0-5°C. The resulting solid was 
filtered, washed with cold methanol (10 mL), dried 
and recrystallized from methanol. Reaction 
completion was monitored by TLC using 7:3  
(n-hexane:ethyl acetate) as mobile phase. 




Yield 76%; mp 177-179°C. IR (KBr) υmax/cm
–1: 
3382 (N-H, broad), 3171 (C-H, aromatic), 2962, 2899 
(C-H, -CH3), 1591 (C=N, benzimidazole ring); 
1H NMR (400 MHz, CDCl3, δ, ppm): 1.54 (d, J = 12 
Hz, 3H), 3.84 (s, 3H), 4.22 (q, J = 10 Hz, 1H), 4.65 (s, 
1H), 6.62 (s, 1H), 6.85-7.31 (m, 9H), 7.52 (s, 1H); 
13C NMR (100 MHz, CDCl3, δ, ppm): 21.6, 34.2, 
60.3, 103.3, 114.0, 117.6, 123.0, 129.3, 130.7, 131.4, 
135.0, 137.9, 145.7, 146.6, 154.8, 177.3; LC-MS 
(m/z): 349 (M+). Anal. calcd. For C19H19N5S: C-65.40, 




Yield 73%; mp 212-214°C. IR (KBr) υmax/cm
–1: 
3379 (N-H, broad), 3170 (C-H, aromatic), 2960, 2895 
(C-H, -CH3), 1594 (C=N, benzimidazole ring); 
1H NMR (400 MHz, CDCl3, δ, ppm): 1.57 (d, J = 11.8 
Hz, 3H), 2.34 (s, 3H), 3.83 (s, 3H), 4.22 (q, J = 9.8 
Hz, 1H), 4.64 (s, 1H), 6.67 (s, 1H), 7.23-7.58 (m, 8H), 
7.62 (s, 1H); 13C NMR (100 MHz, CDCl3, δ, ppm): 
21.8, 23.7, 34.4, 60.1, 103.3, 114.2, 117.8, 123.2, 
127.7, 129.5, 132.4, 135.1, 137.7, 145.3, 146.5, 154.6, 
177.1; LC-MS (m/z): 363 (M+). Anal. calcd. For 
C20H21N5S: C-66.11, H-5.90, N-19.30; Found:  




Yield 78%; mp 235-137°C. IR (KBr) υmax/cm
–1: 
3375 (N-H, broad), 3167 (C-H, aromatic), 2958, 2891 
(C-H, -CH3), 1592 (C=N, benzimidazole ring); 
1H NMR (400 MHz, CDCl3, δ, ppm): 1.56 (d, J = 11.5 
Hz, 3H), 3.27 (s, 3H), 3.66 (s, 3H), 4.27 (q, J= 10.2 
Hz, 1H), 4.61 (s, 1H), 6.63 (s, 1H), 6.81-7.22 (m, 8H), 
7.55 (s, 1H); 13C NMR (100 MHz, CDCl3, δ, ppm):.6, 
34.5, 55.4, 60.2, 105.3, 114.8, 116.6, 121.2, 123.0, 
127.5, 132.3, 139.9, 145.7, 148.4, 154.6, 164.2, 177.0; 
LC-MS (m/z): 379 (M+). Anal. calcd. For 
C20H21N5OS: C-63.36, H-5.55, N-18.41; Found:  




Yield 69%; mp 238-140°C. IR (KBr) υmax/cm
–1: 
3380 (N-H, broad), 3173 (C-H, aromatic), 2964, 2897 
(C-H, -CH3), 1594 (C=N, benzimidazole ring), 731 
(C-Cl); 1H NMR (400 MHz, CDCl3, δ, ppm): 1.55  
(d, J = 11.4 Hz, 3H), 3.66 (s, 3H), 4.29 (q, J = 10.1 




Hz, 1H), 4.61 (s, 1H), 6.65 (s, 1H), 6.81-7.22 (m, 8H), 
7.55 (s, 1H); 13C NMR (100 MHz, CDCl3, δ, ppm): 
21.8, 34.6, 60.6, 105.8, 114.2, 117.6, 123.0, 130.1, 
131.9, 132.3, 132.8, 134.4, 134.7, 137.9, 143.7, 146.2, 
147.6, 177.2; LC-MS (m/z): 383 (M+), 385 (M+2). 
Anal. calcd. For C19H18ClN5S C-59.37, H-4.65, N-




Yield 69%; mp 230-232°C. IR (KBr) υmax/cm
–1: 
3376 (N-H stretching, broad), 3168 (C-H, aromatic), 
2959, 2892 (C-H, -CH3), 1597 (C=N, benzimidazole 
ring), 729 (C-Cl); 1H NMR (400 MHz, CDCl3, δ, 
ppm): 1.73 (d, J = 11.5 Hz, 3H), 3.67 (s, 3H), 4.22 (q, 
J= 10.2 Hz, 1H), 4.62 (s, 1H), 6.64 (s, 1H), 6.80-7.20 
(m, 8H), 7.53 (s, 1H); 13C NMR (100 MHz, CDCl3, δ, 
ppm): 21.6, 34.7, 60.6, 105.6, 114.8, 117.2, 123.2, 
130.8, 131.5, 133.2, 136.3, 137.7, 145.5, 146.6, 154.4, 
177.2; LC-MS (m/z): 383 (M+), 385 (M+2). Anal. 
calcd. For C19H18ClN5S C-59.40, H-4.81, N-18.30; 
Found: C-59.44, H-4.73, N-18.24. 
 
4-(4-bromophenyl)-2-(2-(1-(1-methyl-1H-
benzo[d]imidazol-2-yl)ethyl)hydrazinyl)thiazole (4f)  
Yield 68%; mp 297-300°C. IR (KBr) υmax/cm
–1: 
3386 (N-H stretching, broad), 3175 (C-H, aromatic), 
2961, 2896 (C-H, -CH3), 1593 (C=N, benzimidazole 
ring), 610 (C-Br); 1H NMR (400 MHz, CDCl3, δ, 
ppm): 1.74 (d, J = 11.2 Hz, 3H), 3.61 (s, 3H), 4.21 (q, 
J = 10.4 Hz, 1H), 4.63 (s, 1H), 6.67 (s, 1H), 6.80-7.18 
(m, 8H), 7.56 (s, 1H); 13C NMR (100 MHz, CDCl3, δ, 
ppm): 21.8, 36.2, 60.3, 105.2, 114.6, 117.2, 123.2, 
123.7, 130.7, 134.2, 134.9, 137.7, 143.3, 144.6, 154.3, 
177.0; LC-MS (m/z): 429 (M+), 431 (M+2). Anal. 
calcd. For C19H18BrN5S C-53.25, H-4.30, N-16.29; 




Yield 72%; mp 288-290 oC. IR (KBr) υmax/cm-1: 
3384 (N-H stretching, broad), 3176 (C-H, aromatic), 
2965, 2900 (C-H, -CH3), 1598 (C=N, benzimidazole 
ring), 1018 (C-F); 1H NMR (400 MHz, CDCl3,  
δ, ppm): 1.74 (d, J = 11.5 Hz, 3H), 3.65 (s, 3H), 4.22 
(q, J = 10.5 Hz, 1H), 4.62 (s, 1H), 6.69 (s, 1H), 6.82-
7.24 (m, 8H), 7.57 (s, 1H); 13C NMR (100 MHz, 
CDCl3, δ, ppm): 21.2, 36.6, 60.9, 107.2, 114.8, 118.6, 
121.2, 123.5, 130.8, 132.4, 139.3, 143.9, 146.4, 154.3, 
166.7, 177.8; LC-MS (m/z): 367 (M+), 369 (M+2). 
Anal. calcd. For C19H18FN5S C-62.22, H-5.00, N-
19.13; Found: C-62.11, H-4.94, N-19.06%. 
2-(2-(1-(1-methyl-1H-benzo[d]imidazol-2-
yl)ethyl)hydrazinyl)-4-(4-nitrophenyl)thiazole (4h) 
Yield 78%; mp 299-301°C. IR (KBr) υmax/cm
–1: 
3390 (N-H stretching, broad), 3173 (C-H, aromatic), 
2968, 2895 (C-H, -CH3), 1600 (C=N, benzimidazole 
ring), 1340, 1448 (-NO2); 
1H NMR (400 MHz, 
CDCl3, δ, ppm): 1.74 (d, J = 11.6 Hz, 3H), 3.67 (s, 
3H), 4.25 (q, J = 10.6 Hz, 1H), 4.63 (s, 1H), 6.68 (s, 
1H), 6.86-7.25 (m, 8H), 7.56 (s, 1H); 13C NMR (100 
MHz, CDCl3, δ, ppm): 21.8, 36.7, 60.0, 105.6, 114.8, 
118.6, 123.8, 126.4, 128.4, 139.5, 141.7, 143.7, 146.2, 
149.7, 154.7, 177.4; LC-MS (m/z): 394 (M+). Anal. 
calcd. For C19H18N6O2S C-57.80, H-4.51, N-21.27; 




Yield 67%; mp 257-259°C. IR (KBr) υmax/cm
–1: 
3383 (N-H stretching, broad), 3180 (C-H, aromatic), 
2962, 2896 (C-H stretching, -CH3), 2238 (CN 
stretching, sharp), 1599 (C=N, benzimidazole ring); 
1H NMR (400 MHz, CDCl3, δ, ppm): 1.72 (d, J = 11.3 
Hz, 3H), 3.66 (s, 3H), 4.23 (q, J = 10.3 Hz, 1H), 4.61 
(s, 1H), 6.67 (s, 1H), 6.81-7.22 (m, 8H), 7.55 (s, 1H); 
13C NMR (100 MHz, CDCl3, δ, ppm): 21.6, 36.6, 60.4, 
105.6, 114.4, 116.2, 117.5, 118.8, 123.7, 126.5, 135.5, 
137.6, 139.1, 145.4, 146.2, 154.8, 177.7; LC-MS (m/z): 
374 (M+). Anal. calcd. For C20H18N6S C-64.21, H-4.80, 
N-22.40; Found: C-64.15, H-4.85, N-22.44%. 
 
4-(2,4-dichlorophenyl)-2-(2-(1-(1-methyl-1H-
benzo[d]imidazol-2-yl)ethyl)hydrazinyl) thiazole (4j) 
Yield 65%; mp 261-263°C. IR (KBr) υmax/cm
–1: 3387 
(N-H stretching, broad), 3179 (C-H, aromatic), 2967, 
2899 (C-H, -CH3), 1595 (C=N, benzimidazole ring),738 
(C-Cl); 1H NMR (400 MHz, CDCl3, δ, ppm): 1.72  
(d, J = 11.9 Hz, 3H), 3.66 (s, 3H), 4.23 (q, J = 10.1 Hz, 
1H), 4.63 (s, 1H), 6.68 (s, 1H), 6.82-7.28 (m, 7H), 7.57  
(s, 1H);13C NMR (100 MHz, CDCl3, δ, ppm): 21.4, 
36.8, 60.2, 105.8, 114.2, 117.2, 123.2, 129.2, 130.0, 
132.1, 132.9, 135.9, 137.9, 136.1, 143.3, 144.2, 147.8, 
177.3; LC-MS (m/z): 417 (M+), 419 (M+2), 420 (M+4). 
Anal. calcd. For C19H17Cl2N5S C-54.58, H-4.14,  




Yield 71%; mp 285-287°C. IR (KBr) υmax/cm
–1: 
3388 (N-H stretching, broad), 3178 (C-H, aromatic), 
2977, 2896 (C-H, -CH3), 1598 (C=N, benzimidazole 
ring),1024 (C-F); 1H NMR (400 MHz, CDCl3,  




δ, ppm): 1.78 (d, J = 11.8 Hz, 3H), 3.68 (s, 3H), 4.27  
(q, J = 9.9 Hz, 1H), 4.62 (s, 1H), 6.72 (s, 1H), 7.10-
7.74 (m, 7H), 7.57 (s, 1H); 13C NMR (100 MHz, 
CDCl3, δ, ppm): 21.8, 37.0, 60.9, 104.7, 105.9, 114.8, 
113.2, 117.8, 118.6, 123.6, 132.7, 137.9, 143.9, 144.8, 
149.6, 161.1, 165.3, 179.0; LC-MS (m/z): 385 (M+), 
387 (M+2). Anal. calcd. For C19H17F2N5S C-59.17, H-




The series of newly synthesized compounds were 
screened for their antibacterial activity against 
Escherichia coli (MTCC 443), Pseudomonas 
aeruginosa (MTCC 1688), Staphylococcus aureus 
(MTCC 96), and Klebsiella pneumoniae (recultured) 
bacterial strains by serial plate dilution method27,28. 
Serial dilutions of the drug in Mueller–Hinton broth 
were taken in tubes and their pH was adjusted to 5.0 
using phosphate buffer. A standardized suspension of 
the test bacterium was inoculated and incubated for 
16–18 h at 37°C. The minimum inhibitory 
concentration (MIC) was noted by seeing the lowest 
concentration of the drug at which there was no 
visible growth. A number of antimicrobial discs were 
placed on the agar for the sole purpose of generating 
zones of inhibition in the bacterial lawn. Twenty 
milliliters of agar media was poured into each Petri 
dish. Excess of suspension was decanted and plates 
were dried by placing in an incubator at 37°C for an 
hour. Using an agar punch, wells were made on these 
seeded agar plates and minimum inhibitory 
concentrations of the test compounds in dimethyl 
sulfoxide (DMSO) were added into each labeled well. 
A control was also prepared for the plates in the same 
way using solvent DMSO. The Petri dishes were 
prepared in triplicate and maintained at 37°C for 3–4 
days. Antibacterial activity was determined by 
measuring the diameter of inhibition zone. Activity of 
each compound was compared with ciprofloxacin as 
standard. Zone of inhibition was determined for 3a–k 
and 4a–k and the results are summarized in Table I. 
 
Antifungal studies 
A series of newly synthesized compounds were 
screened for their antifungal activity against 
Table I — Antibacterial activity of the title compounds 3a-k and 4a-k 
Compd 
MIC † in µg/mL and zone of inhibition in mm 
E. coliMTCC 443 P. aeruginosaMTCC 1688 S. aureusMTCC 96 K. pneumoniae (recultured) 
3a 50 (<10) 50 (<10) 50 (<10) 50 (<10) 
3b 50 (10–15) 50 (20-25) 25 (20-25) 25 (<10) 
3c 12.5 (10–15) 12.5 (10–15) 12.5 (18-22) 12.5 (<10) 
3d 6.25 (14–18) 6.25 (14-18) 6.25 (14–18) 6.25 (14–18) 
3e 6.25 (14–18) 6.25 (20-25) 6.25 (14–18) 6.25 (14–18) 
3f 6.25 (14–18) 6.25 (20-25) 6.25 (18-22) 6.25 (14–18) 
3g 6.25 (14–18) 6.25 (20-25) 6.25 (14–18) 6.25 (14–18) 
3h 50 (14–18) 50 (14-18) 50 (<10) 50 (<10) 
3i 12.5 (10–15) 12.5 (10–15) 12.5 (14–18) 12.5 (14-18) 
3j 6.25 (20–25) 50 (<10) 25 (14-18) 25 (10–15) 
3k 6.25 (14–18) 6.25 (20-25) 6.25 (14–18) 6.25 (14–18) 
4a 50 (14-18) 50 (<10) 12.5 (14-18) 50 (<10) 
4b 50 (14–18) 25 (20-25) 25 (14–18) 25 (20-25) 
4c 50 (<10) 50 (20-25) 50 (<10) 50 (<10) 
4d 50 (14-18) 6.25 (20–25) 6.25 (20-25) 50 (14-18) 
4e 6.25 (14–18) 6.25 (14-18) 6.25 (14–18) 6.25 (14–18) 
4f 6.25 (14–18) 6.25 (20-25) 6.25 (14–18) 6.25 (20-25) 
4g 12.5 (14–18) 12.5 (14-18) 12.5 (10–15) 12.5 (14-18) 
4h 12.5 (10–15) 12.5 (14-18) 12.5 (14–18) 12.5 (<10) 
4i 12.5 (14-18) 12.5 (20–25) 12.5 (14-18) 12.5 (<10) 
4j 12.5 (14-18) 12.5 (10–15) 12.5 (14-18) 12.5 (14–18) 
4k 6.25 (20–25) 6.25 (20–25) 6.25 (20-25) 6.25 (20-25) 
Ciprofloxacin (Standard) 6.25 (30–40) 6.25 (25–33) 6.25 (30–40) 6.25 (23–27) 
† The MIC values were evaluated at concentration range, 6.25–50 µg/mL. Above table shows the MIC values in µg/mL and the 
corresponding zone of inhibition in mm. 




Aspergillus flavus (NCIM No. 524), Aspergillus 
fumigates (NCIM No. 902), Penicillium marneffei 
(recultured) and Trichophyton mentagrophytes 
(recultured) in DMSO by serial plate dilution 
method29,30. Sabourands agar media was prepared by 
dissolving peptone (1 g), D-glucose (4 g) and agar (2 
g) in distilled water (100 mL) and adjusting the pH to 
5.7. Normal saline was used to make a suspension of 
spore of fungal strains for lawning. A loopful of 
particular fungal strain was transferred to 3 mL saline 
to get a suspension of corresponding species. Twenty 
milliliters of agar media was poured into each Petri 
dish. Excess of suspension was decanted and plates 
were dried by placing in incubator at 37°C for 1 h. 
Using a punch, wells were made on these seeded agar 
plates minimum inhibitory concentrations of the test 
compounds in DMSO were added into each labeled 
well. A control was also prepared for the plates in the 
same way using solvent DMSO. The Petri dishes were 
prepared in triplicate and maintained at 37°C for 3–4 
days. Antifungal activity was determined by 
measuring the diameter of inhibition zone. Activity  
of each compound was compared with 
ciclopiroxolamine as standard. Zones of inhibition 
were determined for 3a-k and 4a–k and the results are 
summarized in Table II. 
 
In vitro cytotoxicity assay 
In vitro cytotoxicity activity of compounds 3a–k 
and 4a-k was measured by means of the IC50 
using the MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide] assay method. The  
IC50 determination was performed according to the 
National Committee for Clinical Laboratory 
Standards (NCCLS) recommendations. All 
compounds were dissolved in 0.1% DMSO with the 
stock concentration of 10 g/L, and diluted with 
medium freshly before drug administration. Cell lines 
were seeded into 96-well plates at density of 8 × 103 
cells/well. After 24 h seeding, each compound 
dilution was added in duplicate and incubation 
continued at 37°C in a humidified atmosphere 
containing 10% FBS, 1% glutamine, and 50 µM/mL 
gentamicin sulfate in a 5% CO2 and 95% air. After 24 
Table II — Antifungal activity of title compounds 3a-k and 4a-k 
Compd 
MIC† in µg/mL and zone of inhibition in mm 
P. marneffei (recultured) T. mentagrophytes (recultured) A. flavus (NCIM No. 524) A. fumigatus (NCIM No. 902) 
3a 50 (<10) 50 (<10) 50 (<10) 50 (<10) 
3b 12.5 (18-22) 12.5 (18-22) 12.5 (18-22) 12.5 (18-22) 
3c 12.5 (10–15) 12.5 (10–15) 12.5 (18-22) 12.5 (<10) 
3d 6.25 (14–18) 6.25 (14-18) 6.25 (14–18) 6.25 (14–18) 
3e 6.25 (14–18) 6.25 (20-25) 6.25 (14–18) 6.25 (14–18) 
3f 6.25 (14–18) 6.25 (20-25) 6.25 (18-22) 6.25 (14–18) 
3g 6.25 (14–18) 6.25 (20-25) 6.25 (14–18) 6.25 (14–18) 
3h 50 (<10) 50 (<10) 50 (<10) 50 (<10) 
3i 12.5 (18-22) 12.5 (18-22) 12.5 (18-22) 12.5 (18-22) 
3j 12.5 (18-22) 12.5 (18-22) 12.5 (18-22) 12.5 (18-22) 
3k 6.25 (14–18) 6.25 (20-25) 6.25 (14–18) 6.25 (14–18) 
4a 50 (<10) 50 (<10) 50 (<10) 50 (<10) 
4b 50 (14–18) 50 (20-25) 50 (14–18) 50 (20-25) 
4c 50 (<10) 50 (<10) 50 (<10) 50 (<10) 
4d 12.5 (18-22) 12.5 (18-22) 12.5 (20-25) 12.5 (18-22) 
4e 12.5 (18-22) 12.5 (18-22) 12.5 (18-22) 12.5 (18-22) 
4f 12.5 (18-22) 12.5 (18-22) 12.5 (18-22) 12.5 (18-22) 
4g 50 (<10) 50 (<10) 50 (<10) 50 (<10) 
4h 50 (<10) 50 (<10) 50 (<10) 50 (<10) 
4i 50 (<10) 50 (<10) 50 (<10) 50 (<10) 
4j 12.5 (<10) 12.5 (<10) 12.5 (<10) 12.5 (<10) 
4k 6.25 (25–30) 6.25 (25–30) 6.25 (30-37) 6.25 (30-37) 
Ciclopiroxolamin
e (standard) 
6.25 (20–27) 3.25 (27–33) 3.25 (25–30) 6.25 (25–30) 
† The MIC values were evaluated at concentration range, 3.25–50 µg/mL. Above table shows the MIC values in µg/mL and the
corresponding zone of inhibition in mm. 




h, 20 µL MTT reagent was added at 5 mg/mL in PBS 
(filter sterilized, light protected, and stored at  
4°C) per well, and after 4 h of incubation at 37°C, 
MTT was converted to a blue formazan product by 
mitochondrial succinated hydrogenase. This product 
was eluted from cells by addition of 150 mL of 
DMSO. The absorbance at 570 nm was determined by 
an ELISA using a ELX800 microplate 
spectrophotometer. The IC50 value was defined as the 
concentration at which 50% of the cells could survive. 
IC50 values obtained for these compounds are shown 
in Table III. 
 
Conclusion 
By choosing proper experimental conditions we 
have been able to synthesize 2-(2-(1-(1-methyl-1H-
benzo[d]imidazol-2-yl)ethylidene)hydrazinyl)-4-
(aryl) thiazoles 3a-k and 2-(2-(1-(1-methyl-1H-
benzo[d]imidazol-2-yl)ethyl)hydrazinyl)-4-
(aryl)thiazoles 4a-k in good yield and less reaction 
time under simple reaction condition without any 
auxiliary purification and investigate for antimicrobial 
assay and cytotoxicity assay with the hope of 
discovering new structure leads serving aspotential 
broad spectrum pharmacological agents. Results of 
their antibacterial and antifungal screening studies 
revealed that all the newly synthesized compounds 
exhibited moderate to very good activity against 
pathogenic strains. Among all the synthesized 
compounds, 3d, 3e, 3f, 3g, 3k, 4e, 4f and 4k acquire 
very good antibacterial potential, while compounds 
3d, 3e, 3f, 3g, 3k and 4k emerged as highly potential 
antifungal agents at low level of cytotoxic 
concentration. Structure activity relationship studies 
indicate that antimicrobial potential of unreduced 
derivatives 3a-k is higher than reduced derivatives 
4a-k andpresence of halogen substituents (-F -Cl, -Br) 
in phenyl ring which is attached at 4th position of the 
thiazole ring results in enhancement of the 
antibacterial and antifungal activity. Cytotoxicity 
study pointed out that location of halogen substituent 
either on para or ortho and para position make them 
safe candidate without any cytotoxicity effect, 
whereas the same on ortho position has lower IC50 
value. These results conclude that incorporation of 
two distinct heterocycles viz benzimidazole and 
thiazole has enhanced the activity and hence they are 
ideally fitted for further remodelling to attain  
more adequate antibacterial as well antifungal 
compounds.Further structural alterations might lead to 
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